CD20-depleting monoclonal antibody

This page covers all CD20-depleting monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD20.

Targets

CD20

Phase 3 pipeline (1)

• Ocrelizumab Dose 2 and Dose 3 · Genentech, Inc. · Immunology
  Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells.

Patent intelligence

• cd20 depleting monoclonal antibody patent landscape — aggregated cliff calendar, attackable patents, originator estates